News: Astellas Pharma Inc (ALPMF.PK)

ALPMF.PK on OTC Markets Group

15.41USD
23 Jan 2015
Change (% chg)

-- (--)
Prev Close
$15.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
933
52-wk High
$15.53
52-wk Low
$10.49

Search Stocks
Select another date:

Thu, Jan 22 2015

FDA panel backs Astellas drug for invasive fungal infections

- A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's drug for the treatment of rare, often fatal invasive fungal infections that can target patients with blood cancers.

UPDATE 1-FDA panel backs Astellas drug for invasive fungal infections

Jan 22 - A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's drug for the treatment of rare, often fatal invasive fungal infections that can target patients with blood cancers.

BRIEF-Astellas announces end of license agreement with Janssen Biotech

* Announces end of license agreement with janssen biotech to develop oral janus kinase inhibitor

CORRECTED-UPDATE 2-Dendreon files for bankruptcy as cancer vaccine disappoints

(Corrects paragraph 6 to say Xtandi is marketed by Medivation and Astellas)

REFILE-TABLE-Astellas -6-MTH group results (IFRS)

(Operating forecast is core operating forecast, EPS forecast is core EPS forecast.Adds core net profit) Oct 31 - Astellas Pharma Inc. CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Sep 30, 2014 Sep 30, 2013 Mar 31, 2015 LATEST YEAR-AGO COMPANY RESULTS

U.S. FDA approves expanded use of Medivation prostate cancer drug

- U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

UPDATE 1-U.S. FDA approves expanded use of Medivation prostate cancer drug

Sept 10 - U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

Select another date:
Search Stocks